A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction.
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 07 Nov 2011 Actual initiation date changed from Oct 2007 to Apr 2006 as reported by ClinicalTrials.gov.
- 07 Nov 2011 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
- 03 Oct 2006 New trial record.